First Patients are Vaccinated in IMPRINT*, immatics' Pivotal Phase III Trial ... - PR Newswire (press release) PDF Print
PR Newswire (press release)
We look forward to confirming the positive overall survival data seen in the phase II study as advanced renal cell cancer still has a very high unmet medical need." Paul Higham, CEO of immatics, added: "An overall survival benefit combined with a ...
First Patients are Vaccinated in IMPRINT*, immatics' Pivotal Phase III Trial

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.